Phase 2 N=115 S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
Leukemia
Primary: Complete Remission (CR) Rate (Including CR With Incomplete Recovery) — 27; 14; 14 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=116 Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Chronic Myeloid Leukemia
Primary: Participants With a Response — 4; 9; 16; 2 participants
Phase 2 N=60 Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Leukemia · Myelodysplastic Syndromes
Primary: Number of Patients Experiencing Regimen-related Toxicity Events in Study Population — 2; 5 participants
Phase 2 N=197 Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Adult Acute Myeloid Leukemia in Remission · Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Primary: Proportion of Patients With Clinical Response — 0.32; 0.27; 0.46; 0.17 Proportion of patients
Phase 2 N=50 Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm
Acute Leukemia of Ambiguous Lineage · Acute Myeloid Leukemia · Myeloid Neoplasm
Primary: Feasibility Defined as Proportion of Patients Willing to be Randomized to Either Intensive or Non-intensive Induction and Post Remission Chemotherapy — 3; 47 Participants
Phase 2 N=38 Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia Post Cytotoxic Therapy · Recurrent Childhood Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia
Primary: Number of Participants With a Dose-limiting Toxicity — 1 Participants
Phase 2 N=73 Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia · Therapy-Related Acute Myeloid Leukemia
Primary: Rate of Complete Remission and Mortality in the Entire Cohort of Older Patients — 21.9; 52.0 percentage of subjects
Phase 2 N=66 Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm
Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose (MTD) of Gemtuzumab Ozogamicin (GO) When Added to GCLAM (Phase 1) — NA; NA Participants
Phase 3 N=15 A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Primary: Overall Survival (OS) — 9.82; 9.23; 5.24 months — p=0.523
Phase 2 N=77 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Biphenotypic Leukemia · Acute Leukemia of Ambiguous Lineage
Primary: Chronic GVHD — 17; 20; 14; 17 Participants
Phase 2 N=160 Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes
Acute Biphenotypic Leukemia · Acute Lymphoblastic Leukemia in Remission · Acute Myeloid Leukemia in Remission
Primary: Time to Neutrophil Engraftment — 20.0; 22.0 days
Phase 2 N=24 MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Primary: Response (Complete and Partial Response) in Patients With Myeloid Disorders — 0; 1; 2; 5 Participants
Phase 2 N=47 Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303)
Leukemia, Myelocytic, Acute
Primary: Probability of Disease-free Survival (DFS) at 6 Months Post-transplant (Death or Relapse Will be Considered Events for This Endpoint) — 81.8 percentage of patients
Phase 2 N=65 Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Neutropenia
Primary: Number of Participants With Proven or Probable Invasive Fungal Infections (IFIs) — 4 Participants
Phase 1 N=23 Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia
Acute Myeloid Leukemia · Essential Thrombocythemia
Primary: Recommended Phase 2 Dose of LY573636-Sodium in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Essential Thrombocythemia (ET)